The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.

The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.

Described herein are compositions and methods to cryopreserve sporozoites. In some aspects, the method can include the step of placing harvested salivary glands containing sporozoites into an insect-based medium.

An object of the present invention is to provide an animal cell culture method which is high in protein productivity. Provided is a method for culturing animal cells in a culture medium, wherein the culture medium comprises a nucleic acid component(s) (deoxyuridine, thymidine, and/or deoxycytidine, or a salt(s) thereof). Also provided is a method for producing a protein, the method comprising the step of culturing animal cells expressing the protein in a culture medium, wherein the culture medium comprises a nucleic acid component(s).

The subject invention relates to enhancing for the production of microorganisms and/or their growth by-products by treating and/or preventing bacteriophage contamination of bacterial cultures. Advantageously, the methods can help reduce the likelihood of total and/or partial culture loss through the direct control of bacteriophages and/or prophages that may be present in the culture. In certain embodiments, the method comprise applying an antiviral composition comprising, for example, ribavirin, to the nutrient medium in which a microorganism is being cultivated.

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.

The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.

The present invention relates to a production method of a systemic sclerosis disease model using keratinocytes and fibroblasts differentiated from induced pluripotent stem cells derived from patients with systemic sclerosis, a systemic sclerosis disease model produced thereby, and a method for screening a therapeutic agent for systemic sclerosis using the same.

The systemic sclerosis disease model produced by the above production method can be effectively used for preventing or treating systemic sclerosis.

Methods for the ex vivo use of NAD to remove T cells that can potentially cause graft-verus-host disease (GvHD) from hematopoietic stem cell sources. Hematopoietic stem cell sources include bone marrow, cord blood, and peripheral blood (including mobilized peripheral blood). The present invention is a method including steps for using the hematopoietic stem cell sources treated with NAD for hematopoietic stem cell transplants (HSCTs). HSCTs are used as the standard-of-care in many diseases including several types of cancer and several genetic disorders. The majority of these transplants are allogeneic, in which the stem cell source comes from a donor who is a different individual than the intended recipient. Allogeneic HSCTs carry a risk of causing GvHD, in which donor T cells attack the recipient.

A three-dimensional (3D) liver organoid obtained through the differentiation of induced pluripotent stem cells (IPSCs) in laboratory culture medium and a production method of the 3D hepatic organoid are provided. The production method includes the following steps: differentiating the IPSCs into a definitive endoderm in a medium containing Activin A, Wnt3a, and R-spo1 factors; adding 5 ng/ml R-spo 1 during IPSC differentiation to increase an amount of EpCAM+endoderm progenitor cells; cell sorting of the EpCAM+endoderm progenitor cells through a fluorescence-activated cell sorting (FACS) method; culturing a sorted EpCAM+endoderm progenitor cells in a 3D Matrigel medium of 37° C., 5% CO2, 95% humidity and 7.2-7.5 pH.